Menu
Back to Journals » Drug Design, Development and Therapy » Volume 7
Daclatasvir: potential role in hepatitis C
Authors Lee C
Received 29 July 2013
Accepted for publication 29 August 2013
Published 16 October 2013 Volume 2013:7 Pages 1223—1233
DOI https://doi.org/10.2147/DDDT.S40310
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Choongho Lee
College of Pharmacy, Dongguk University-Seoul, Goyang, Republic of Korea
Abstract: Chronic hepatitis C virus (HCV) infection is responsible for the development of liver cirrhosis and hepatocellular carcinoma. It has been a tremendous burden on global health care systems. With the advent of a number of new direct-acting and host-targeting antiviral agents, current interferon-α- and ribavirin-based HCV therapy has started to move towards an interferon-sparing or even interferon-free strategy. In this regard, a recently identified NS5A inhibitor, daclatasvir, showed a great promise in clinical trials as another new class of direct-acting anti-HCV therapeutics, with a distinct mechanism of action. In this review, a variety of preclinical as well as clinical proof-of-concept studies of daclatasvir, including the studies of its discovery, mechanism of action, viral resistance, and host polymorphism profiles are reviewed. In addition, a role of daclatasvir in the future therapy for HCV patients is discussed briefly.
Keywords: hepatitis C virus, nonstructural protein 5A, NS5A inhibitor, hepatitis C treatment
Corrigendum for this paper has been published
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.